DNA hydroxymethylation controls cardiomyocyte gene expression in development and hypertrophy
Citations Over TimeTop 1% of 2016 papers
Abstract
Methylation at 5-cytosine (5-mC) is a fundamental epigenetic DNA modification associated recently with cardiac disease. In contrast, the role of 5-hydroxymethylcytosine (5-hmC)-5-mC's oxidation product-in cardiac biology and disease is unknown. Here we assess the hydroxymethylome in embryonic, neonatal, adult and hypertrophic mouse cardiomyocytes, showing that dynamic modulation of hydroxymethylated DNA is associated with specific transcriptional networks during heart development and failure. DNA hydroxymethylation marks the body of highly expressed genes as well as distal regulatory regions with enhanced activity. Moreover, pathological hypertrophy is characterized by a shift towards a neonatal 5-hmC distribution pattern. We also show that the ten-eleven translocation 2 (TET2) enzyme regulates the expression of key cardiac genes, such as Myh7, through 5-hmC deposition on the gene body and at enhancers. Thus, we provide a genome-wide analysis of 5-hmC in the cardiomyocyte and suggest a role for this epigenetic modification in heart development and disease.
Related Papers
- → Uncovering the role of 5-hydroxymethylcytosine in the epigenome(2011)762 cited
- → 5-Hydroxymethylcytosine: a Potential Therapeutic Target in Cancer(2014)24 cited
- → Discrimination between 5-hydroxymethylcytosine and 5-methylcytosine in DNA by selective chemical labeling(2013)12 cited
- → Selective oxidation of 5-hydroxymethylcytosine with micelle incarcerated oxidants to determine it at single base resolution(2015)4 cited
- → [Recent research on childhood hypertrophic cardiomyopathy caused by MYH7 gene mutations].(2023)5 cited